Erratum: Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome (Journal of Child Neurology (2012) 27:7 (875-884) DOI: 10.1177/0883073811428816);Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome

Journal of Child Neurology

Volumn 27, Issue 7, 2012, Pages 875-884

  Tate, Elizabeth D ^a   Pranzatelli, Michael R ^a   Verhulst, Steven J ^a   Markwell, Stephen J ^a   Franz, David Neal ^b   Graf, William D ^c   Joseph, S Anne ^d   Khakoo, Yasmin N ^e   Lo, Warren D ^f   Mitchell, Wendy G ^g   Sivaswamy, Lalitha ^h  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c YALE UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h WAYNE STATE UNIVERSITY   (United States)

Author keywords

ACTH; Adrenocorticotropic hormone; Corticosteroid; Corticotropin; Dancing eyes; Intravenous immunoglobulin; Kinsbourne syndrome; Neuroblastoma; Paraneoplastic; Rituximab

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ACNE; ANEMIA; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE DISORDER; FEMALE; FEVER; FLUSHING; FRACTURE; HEADACHE; HIRSUTISM; HUMAN; HUNGER; HYPERTENSION; HYPOGLYCEMIA; IMMUNOTHERAPY; IRRITABILITY; LEG PAIN; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MOTOR ACTIVITY; ODOR; OPSOCLONUS MYOCLONUS SYNDROME; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SEPTICEMIA; SIDE EFFECT; SINGLE BLIND PROCEDURE; STOMACH PAIN; SWEATING; SWELLING; SYNCOPE; VOMITING; WEIGHT GAIN;

EID: 84862876679     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073812462180     Document Type: Erratum

References (36)

1. Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry. 1962 ; 25: 271-276
2. Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 U.S. cases of pediatric opsoclonus-myoclonus. J Pediatric Oncol Nurs. 2005 ; 22: 8-19 (Pubitemid 40091116)
3. Pranzatelli MR, Huang YY, Tate E, et al. Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Mov Disord. 1998 ; 13: 522-528 (Pubitemid 28221507)
4. Snead OC III, Benton JW, Hosey LC, et al. Treatment of infantile spasms with high-dose ACTH: efficacy and plasma levels of ACTH and cortisol. Neurology. 1989 ; 39: 1027-1031 (Pubitemid 19217467)
5. Sugie H, Sugie Y, Akimoto H, Endo K, Shirai M, Ito M. High-dose IV human immunoglobulin in a case with infantile opsoclonus polymyoclonia syndrome. Acta Paediatr. 1992 ; 18: 371-372
6. Pranzatelli MR. Friendly fire. Discover. April 2000 ;: 35-36
7. Pranzatelli MR, Tate ED, Travelstead AL, et al. Cyclophosphamide therapy in pediatric opsoclonus-myoclonus. Ann Neurol. 2005 ; 58 (suppl 9). S90
8. Pranzatelli MR, Tate ED, Travelstead AL, et al. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil. J Child Neurol. 2009 ; 24: 316-322
9. Pranzatelli MR, Travelstead A, Tate ED, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology. 2004 ; 62: 1526-1532 (Pubitemid 38608190)
10. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol. 2006 ; 28: 585-593 (Pubitemid 44496336)
11. Pranzatelli MR. On the molecular mechanism of adrenocorticotrophic hormone: neurotransmitters and receptors. Exp Neurol. 1994 ; 125: 142-161 (Pubitemid 24067615)
12. Wikberg JE, Muceniece R, Mandrika I, et al. New aspects on the melanocortins and their receptors. Pharmacol Res. 2000 ; 42: 393-420
13. Pranzatelli MR, Tate ED, Hoefgen ER, Swan JA, Colliver JA. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome. Cytokine. 2008 ; 44: 26-32
14. Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol. 1996 ; 19: 1-47 (Pubitemid 26026319)
15. Baerenwaldt A, Biburger M, Nimmerjahn F. Mechanisms of action of intravenous immunoglobulins. Expert Rev Clin Immunol. 2010 ; 6: 425-434
16. Leen WG, Weemaes CM, Verbeek MM, Willemsen MA, Rotteveel JJ. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome. Pediatr Neurol. 2008 ; 39: 213-217
17. Corapcioglu F, Mutlu H, Kara B, et al. Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma. Pediatr Hematol Oncol. 2008 ; 25: 756-761
18. Pranzatelli MR, Tate ED, Swan JA, et al. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord. 2010 ; 25: 238-242
19. Veneselli E, Conte M, Biancheri R, Acquaviva A, De Bernardi B. Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma. Med Pediatr Oncol. 1998 ; 30: 15-17 (Pubitemid 128765906)
20. Wilken B, Baumann M, Bien CG, Hero B, Rostasy K, Hanefeld F. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol. 2008 ; 12: 51-55 (Pubitemid 350253170)
21. Koh PS, Raffensperger JG, Berry S, et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr. 1994 ; 125: 712-716 (Pubitemid 24350179)
22. Hammer MS, Larsen MB, Stack CV. Outcome of children with opsoclonus-myoclonus regardless of etiology. Pediatr Neurol. 1995 ; 13: 21-24
23. Pohl KRE, Pritchard J, Wilson J. Neurological sequelae of the dancing eye syndrome. Eur J Pediatr. 1996 ; 155: 237-244 (Pubitemid 26053363)
24. Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr. 2001 ; 139: 552-559 (Pubitemid 32977271)
25. Pranzatelli MR, Tate ED, Kinsbourne M, Caviness VS, Mishra B. Forty-one year follow-up of childhood-onset opsoclonus-myoclonus: cerebellar atrophy, multiphasic relapses, response to IVIG. Mov Disord. 2002 ; 17: 1387-1390 (Pubitemid 36041365)
26. Klein A, Schmitt B, Boltshauser E. Long-term outcome of ten children with opsoclonus-myoclonus syndrome. Eur J Pediatr. 2007 ; 166: 359-363 (Pubitemid 46295094)
27. Partikian A, Mitchell WG. Major adverse events associated with treatment of infantile spasms. J Child Neurol. 2007 ; 22: 1360-1366 (Pubitemid 351453800)
28. Prasad P, Nania JJ, Shankar SM. Pneumocystis pneumonia in children receiving chemotherapy. Pediatr Blood Cancer. 2008 ; 50: 896-898 (Pubitemid 351354814)
29. Quittel LM, Fisher M, Foley CM. Pneumocystis carinii pneumonia in infants given adrenocorticotropic hormone for infantile spasms. J Pediatr. 1987 ; 110: 901-903 (Pubitemid 17080441)
30. Goetting MG. Fatal pneumocystis pneumonia from ACTH therapy for infantile spasms. Ann Neurol. 1986 ; 19: 307-308 (Pubitemid 16111086)
31. Hung MC, Chen CJ, Wu KG, et al. Subcutaneously implanted central venous access device infection in pediatric patients with cancer. J Microbiol Immunol Infect. 2009 ; 42: 166-171
32. Valerio G, Gallè F, Mancusi C, et al. Pattern of fractures across pediatric age groups: analysis of individual and lifestyle factors. BMC Public Health. 2010 ; 656: 10
33. Huber BM, Bold IB, Sauvain MJ, Flück CE. Adrenal insufficiency after glucocorticoid withdrawal in children with rheumatic diseases. Acta Paediatr. 2010 ; 99: 1889-1893
34. Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinology & Metabolism Clinics of North America. 2005 ; 34: 341-356 (Pubitemid 40602725)
35. Medication Guide: H.P. Acthar Gel (repository corticotropin injection). http://www.fda.gov/downloads/Drugs/DrugSafety/UCM231714.pdf. Accessed October 28, 2011.
36. Camfield P, Camfield C. Sudden unexpected death in people with epilepsy: a pediatric perspective. Semin Pediatr Neurol. 2005 ; 12: 10-14 (Pubitemid 40558909)